Cover Image
市場調查報告書

Toleranzia AB的產品平台分析

Toleranzia AB - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 285614
出版日期 內容資訊 英文 21 Pages
訂單完成後即時交付
價格
Back to Top
Toleranzia AB的產品平台分析 Toleranzia AB - Product Pipeline Review - 2015
出版日期: 2015年12月23日 內容資訊: 英文 21 Pages
簡介

Toleranzia AB是總公司設置於瑞典的生物科技企業,正在開發自體免疫疾病的治療藥,並提供技術。基於利用融合蛋白質來治療免疫功能不全的技術平台為基礎,提供罕見疾病,Ⅰ形式糖尿病,類風濕性關節炎,多發性硬化症等的治療藥。

本報告提供Toleranzia AB的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,加上最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Toleranzia AB的基本資料

  • Toleranzia AB概要
  • 主要資訊
  • 企業資料

Toleranzia AB:R&D概要

  • 主要的治療範圍

Toleranzia AB:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Toleranzia AB:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Toleranzia AB:藥物簡介

  • Recombinant Protein for Allergy
  • Recombinant Protein for Autoimmune Orphan Indications
  • Recombinant Protein for Multiple Sclerosis
  • Recombinant Protein for Myasthenia Gravis
  • Recombinant Protein for Rheumatoid Arthritis
  • Recombinant Protein for Sjogren's syndrome
  • Recombinant Protein for Type 1 Diabetes

Toleranzia AB:開發平台分析

  • 各給藥途徑
  • 各分子類型

Toleranzia AB:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07898CDB

Summary

Global Markets Direct's, 'Toleranzia AB - Product Pipeline Review - 2015', provides an overview of the Toleranzia AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Toleranzia AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Toleranzia AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Toleranzia AB's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Toleranzia AB's pipeline products

Reasons to buy

  • Evaluate Toleranzia AB's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Toleranzia AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Toleranzia AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Toleranzia AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Toleranzia AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Toleranzia AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Toleranzia AB Snapshot
    • Toleranzia AB Overview
    • Key Information
    • Key Facts
  • Toleranzia AB - Research and Development Overview
    • Key Therapeutic Areas
  • Toleranzia AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Toleranzia AB - Pipeline Products Glance
    • Toleranzia AB - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Toleranzia AB - Drug Profiles
    • Recombinant Protein for Allergy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Autoimmune Orphan Indications
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Myasthenia Gravis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Rheumatoid Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Sjogren's Syndrome
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Type 1 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Toleranzia AB - Pipeline Analysis
  • Toleranzia AB - Pipeline Products by Route of Administration
  • Toleranzia AB - Pipeline Products by Molecule Type
  • Toleranzia AB - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Toleranzia AB, Key Information
  • Toleranzia AB, Key Facts
  • Toleranzia AB - Pipeline by Indication, 2015
  • Toleranzia AB - Pipeline by Stage of Development, 2015
  • Toleranzia AB - Monotherapy Products in Pipeline, 2015
  • Toleranzia AB - Preclinical, 2015
  • Toleranzia AB - Pipeline by Route of Administration, 2015
  • Toleranzia AB - Pipeline by Molecule Type, 2015

List of Figures

  • Toleranzia AB - Pipeline by Top 10 Indication, 2015
Back to Top